Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Biotechnology Research
Radiopharm Theranostics is a Biotechnology Research brand in Sydney. Ownership is privately held; it publishes at radiopharmtheranostics.com. It holds one address on record, all in Australia. The record counts 24 people. Tagged cancer, diagnostics and health. One Australian registration (ABN) is a confirmed match. Its latest round on record is Post IPO equity, US$5.0M. It is listed alongside two similar brands, mostly in Pharmaceutical Manufacturing.
radiopharmtheranostics.com LinkedIn
ABN57647877889
| RADIOPHARM THERANOSTICS LIMITED | ABN 57647877889 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
| Rounds | 3 |
|---|---|
| Axis | 2021 to 2026 |
| Post IPO equity · 9 Feb 2025 | US$ 5.0M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
One Victoria entity on the ABR. RADIOPHARM THERANOSTICS LIMITED (ABN 57 647 877 889), high confidence.
The record holds 24 counted staff profiles at January 2026, above the self-reported 2–10 band.
One address on record, Australia only. Primary: Sydney.
Three rounds. Latest 9 February 2025: post IPO equity, US$5,000,000, investor Lantheus Holdings.
27 tags on the brand's own list, among them cancer, diagnostics and health.
6 profiles list Radiopharm Theranostics as a peer — 68th percentile in Biotechnology Research. It lists ten peers of its own. Clarity Pharmaceuticals lists it back.